MB-101 is under clinical development by Mustang Bio and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MB-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MB-101 overview
MB-101 is under development for the treatment of recurrent or refractory glioblastoma multiforme. It is administered through intratumoral infusion or intracavitary or intraventricular catheter, intracerebroventricular (ICV) delivery. The therapy comprises of central memory enriched T cells lentivirally transduced to express an IL13R-apha2-specific, hinge-optimized, 41BB-costimulatory chimeric receptor and a truncated CD19. It acts by targeting interleukin 13 receptor alpha-2 (IL13R alpha 2).
Mustang Bio overview
Mustang Bio is an US based developer of cell and gene therapies for the treatment of AML and brain cancer.
For a complete picture of MB-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
